journal article·2024-09Open access

Light‐Activated In Situ Vaccine with Enhanced Cytotoxic T Lymphocyte Infiltration and Function for Potent Cancer Immunotherapy

Xian An, Zhuang Chen, Yi Luo, Peng Yang, Zuo Yang, Tiannan Ji, Yajing Chi, Shuyuan Wang, Ruili Zhang, Zhongliang Wang, Jianxiong Li

Advanced Science· Volume 11· Issue 33

Abstract

Abstract In situ cancer vaccination is an attractive strategy that stimulates protective antitumor immunity. Cytotoxic T lymphocytes (CTLs) are major mediators of the adaptive immune defenses, with critical roles in antitumor immune response and establishing immune memory, and are consequently extremely important for in situ vaccines to generate systemic and lasting antitumor efficacy. However, the dense extracellular matrix and hypoxia in solid tumors severely impede the infiltration and function of CTLs, ultimately compromising the efficacy of in situ cancer vaccines. To address this issue, a robust in situ cancer vaccine, Au@MnO2 nanoparticles (AMOPs), based on a gold nanoparticle core coated with a manganese dioxide shell is developed. The AMOPs modulated the unfavorable tumor microenvironment (TME) to restore CTLs infiltration and function and efficiently induced immunogenic cell death. The Mn2+‐mediated stimulator of the interferon genes pathway can be activated to further augment the therapeutic efficacy of the AMOPs. Thus, the AMOPs vaccine successfully elicited long‐lasting antitumor immunity to considerably inhibit primary, recurrent, and metastatic tumors. This study not only highlights the importance of revitalizing CTLs efficacy against solid tumors but also makes progress toward overcoming TME barriers for sustained antitumor immunity.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Medical School of Chinese PLA & Department of Oncology Chinese PLA General Hospital Beijing 100193 P. R. China

Lab of Molecular Imaging and Translational Medicine (MITM) Engineering Research Center of Molecular & Neuro‐imaging Ministry of Education School of Life Science and Technology Xidian University Xi'an Shaanxi 710126 P. R. China

Department of Emergency The Fifth Medical Center of PLA General Hospital Beijing 100193 P. R. China

School of Medicine Nankai University Tianjin 300071 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (50)

Show source-provided references
1. 10.1038/s43018-022-00418-610.1038/s43018-022-00418-6 ↗
2. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
3. 10.1016/j.it.2016.09.00210.1016/j.it.2016.09.002 ↗
4. 10.1002/adma.20210972610.1002/adma.202109726 ↗
5. 10.1002/anie.20201559010.1002/anie.202015590 ↗
6. 10.1038/s41565-022-01098-010.1038/s41565-022-01098-0 ↗
7. 10.1038/s41571-023-00789-410.1038/s41571-023-00789-4 ↗
8. 10.1016/j.ccell.2023.11.00510.1016/j.ccell.2023.11.005 ↗
9. 10.1038/nature2514410.1038/nature25144 ↗
10. 10.1038/nature2463310.1038/nature24633 ↗
11. 10.1002/adma.20200464710.1002/adma.202004647 ↗
12. 10.1002/adma.20230719310.1002/adma.202307193 ↗
13. 10.1016/j.nantod.2022.10146610.1016/j.nantod.2022.101466 ↗
14. 10.1038/s41467-023-40207-y10.1038/s41467-023-40207-y ↗
15. 10.1126/sciadv.aba402410.1126/sciadv.aba4024 ↗
16. 10.1002/adma.20221148510.1002/adma.202211485 ↗
17. 10.1021/acsnano.3c1022510.1021/acsnano.3c10225 ↗
18. 10.1002/adhm.20230108310.1002/adhm.202301083 ↗
19. 10.1016/j.biomaterials.2022.12181010.1016/j.biomaterials.2022.121810 ↗
20. 10.1016/j.trecan.2016.09.00710.1016/j.trecan.2016.09.007 ↗
21. 10.1002/adma.20210665410.1002/adma.202106654 ↗
22. 10.1002/adfm.20200105910.1002/adfm.202001059 ↗
23. 10.1126/sciadv.ade625710.1126/sciadv.ade6257 ↗
24. 10.1002/adfm.20230673410.1002/adfm.202306734 ↗
25. 10.1016/j.nantod.2023.10192010.1016/j.nantod.2023.101920 ↗
26. 10.1021/acs.accounts.3c0077110.1021/acs.accounts.3c00771 ↗
27. 10.1038/s41565-023-01553-610.1038/s41565-023-01553-6 ↗
28. 10.1021/jacs.3c0862210.1021/jacs.3c08622 ↗
29. 10.1038/s41586-021-04057-210.1038/s41586-021-04057-2 ↗
30. 10.1038/s41590-020-00834-910.1038/s41590-020-00834-9 ↗
31. 10.1038/s41467-023-39035-x10.1038/s41467-023-39035-x ↗
32. 10.1002/smll.20220495110.1002/smll.202204951 ↗
33. 10.1016/j.biomaterials.2018.05.05110.1016/j.biomaterials.2018.05.051 ↗
34. 10.1021/acsami.1c0043010.1021/acsami.1c00430 ↗
35. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
36. 10.1021/acsnano.2c1035210.1021/acsnano.2c10352 ↗
37. 10.1002/advs.20210007410.1002/advs.202100074 ↗
38. 10.1002/anie.20210986310.1002/anie.202109863 ↗
39. 10.1002/adhm.20200039410.1002/adhm.202000394 ↗
40. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
41. 10.1126/science.120834710.1126/science.1208347 ↗
42. 10.1038/s41423-021-00669-w10.1038/s41423-021-00669-w ↗
43. 10.1002/adma.20230451410.1002/adma.202304514 ↗
44. 10.1016/j.nantod.2022.10140510.1016/j.nantod.2022.101405 ↗
45. 10.1038/s41467-023-38601-710.1038/s41467-023-38601-7 ↗
46. 10.1038/nrc118710.1038/nrc1187 ↗
47. 10.7150/thno.7994510.7150/thno.79945 ↗
48. 10.1016/j.cej.2022.13571210.1016/j.cej.2022.135712 ↗
49. 10.1016/j.cej.2022.13813910.1016/j.cej.2022.138139 ↗
50. 10.1126/sciadv.add359910.1126/sciadv.add3599 ↗